Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

News Conference News AHA 2015

RIVER-PCI Subanalysis: No Impact of Ranolazine on Quality of Life

L.A. McKeown

November 09, 2015

News Conference News AHA 2015

AHA 2015 Promises Appropriate PCI, Ticagrelor Tolerance, Outcomes With IVUS, and More

Shelley Wood

November 05, 2015

Presentation TCT 2015

RIVER-PCI: A Prospective, Double-Blind, Placebo-Controlled Randomized Trial of Ranolazine in Patients With Incomplete Revascularization After Coronary Intervention

Presenter: Sunil V. Rao, Giora Weisz

October 13, 2015

Presentation TCT 2015

RIVER-PCI: A Prospective, Double-blind, Placebo-Controlled Randomized Trial of Ranolazine in Patients With Incomplete Revascularization After Coronary Intervention

Presenter: Giora Weisz

October 13, 2015

News Conference News TCT 2015

RIVER-PCI: No Advantage to Ranolazine in Patients With Incomplete Revascularization

Yael L. Maxwell

October 13, 2015

News Industry News

Medical Therapy With Ranolazine Did Not Reduce Adverse Events In Patients With Persistent Untreated Heart Artery Blockages After Percutaneous Coronary Intervention

October 13, 2015

News Industry News

Medtronic Drug-Coated Balloon Shows Strong Clinical and Economic Benefit in Treatment of Peripheral Artery Disease

September 16, 2014

News Daily News

EVAR Results in Higher Patient-Level Safety Benefit than Surgery for AAA

L.A. McKeown

July 17, 2014

News Daily News

Zilver PTX 2-Year Results Published: Superior Safety, Efficacy vs. Angioplasty Sustained

April 12, 2013

News Industry News

Cook Medical’s Zilver® PTX® Earns FDA Approval As First Drug-Eluting Stent in U.S. to Treat Peripheral Arterial Disease

November 14, 2012

News Daily News

Watchman Device for LAA Closure Provides Net Clinical Benefit vs. Warfarin in A-fib Patients

September 27, 2012

News Daily News

Meta-analysis: Paclitaxel-Coated Balloon Reduces TLR in Femoropopliteal Disease

August 07, 2012

News Daily News

Meta Análisis: El Balón Recubierto de Paclitaxel Reduce la RLD en la Enfermedad Femoropoplítea

August 07, 2012

News Daily News

Antianginal Drug May Reduce Periprocedural MI in Elective PCI

Yael L. Maxwell

June 08, 2012

News Industry News

Gilead Sciences, CRF commence Ranolazine trial to treat MACE

November 09, 2011

Advertisement

RIVER-PCI Subanalysis: No Impact of Ranolazine on Quality of Life

AHA 2015 Promises Appropriate PCI, Ticagrelor Tolerance, Outcomes With IVUS, and More

RIVER-PCI: A Prospective, Double-Blind, Placebo-Controlled Randomized Trial of Ranolazine in Patients With Incomplete Revascularization After Coronary Intervention

RIVER-PCI: A Prospective, Double-blind, Placebo-Controlled Randomized Trial of Ranolazine in Patients With Incomplete Revascularization After Coronary Intervention

RIVER-PCI: No Advantage to Ranolazine in Patients With Incomplete Revascularization

Medical Therapy With Ranolazine Did Not Reduce Adverse Events In Patients With Persistent Untreated Heart Artery Blockages After Percutaneous Coronary Intervention

Medtronic Drug-Coated Balloon Shows Strong Clinical and Economic Benefit in Treatment of Peripheral Artery Disease

EVAR Results in Higher Patient-Level Safety Benefit than Surgery for AAA

Zilver PTX 2-Year Results Published: Superior Safety, Efficacy vs. Angioplasty Sustained

Cook Medical’s Zilver® PTX® Earns FDA Approval As First Drug-Eluting Stent in U.S. to Treat Peripheral Arterial Disease

Watchman Device for LAA Closure Provides Net Clinical Benefit vs. Warfarin in A-fib Patients

Meta-analysis: Paclitaxel-Coated Balloon Reduces TLR in Femoropopliteal Disease

Meta Análisis: El Balón Recubierto de Paclitaxel Reduce la RLD en la Enfermedad Femoropoplítea

Antianginal Drug May Reduce Periprocedural MI in Elective PCI

Gilead Sciences, CRF commence Ranolazine trial to treat MACE

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content